Despite bruising market, two biotechs price their IPOs while another launches its Nasdaq bid

The current market situation for biotechs is certainly not ideal, but that is not deterring a few companies from diving into the waters of Wall Street.

Two companies, Boston-based HilleVax and San Diego-based Belite Bio, will make their Nasdaq debuts Friday, while another biotech that has some familiar names attached filed for an IPO.

After filing earlier this month HilleVax grabs more than $150M

HilleVax, a norovirus vaccine developer spun out from Takeda by late biotech legend Tachi Yamada, went public on the back of a $150 million-plus debut and priced its IPO at $17 per share.

HilleVax is a little over 10 months from being spun out of Takeda and has backing from Frazier Healthcare Partners. The startup launched with a norovirus vaccine candidate that had already completed several Phase I and Phase II trials.

The biotech also estimates that the net proceeds from the…
Click here to view original post